All In Biotech

Drug Trial Radar · NCT04275180

Efficacy Argatroban in Ischemic Stroke With Early Deterioration (EASE)

Efficacy of Argatroban in Acute Ischemic Stroke With Early Neurological Deterioration

Last checked: Nov 20, 2026Latest source record: Apr 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 628 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

628

Actual

Start

Mar 21, 2020

Primary completion

Jul 31, 2022

Study completion Jan 31, 2023

Sponsor

Sponsor type
Academic, hospital or other
First posted
Feb 19, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Acute ischemic stroke (AIS) has the characteristics of high morbidity, high mortality, high disability rate and high recurrence rate. Progressive cerebral infarction (PIS) is a subtype of AIS, accounting for 10% - 40%. Because of the gradual aggravation of neurological deficit symptoms, it has a higher rate of disability and death, which brings heavy mental and economic burden to families, society and the country. The progress of acute cerebral infarction is generally within 6 hours to 1 week after the onset of the disease. At present, it is considered that thrombus prolongation is one of the important pathogenesis of PIS. Heparin can reduce the incidence of post-stroke embolism, but its benefits are offset by the risk of hemorrhage due to the high risk of hemorrhage. The 2013AHA guidelines in the United States do not recommend it as a routine anticoagulant therapy. Therefore, reducing the risk of bleeding is the key to the anticoagulation therapy of PIS. Argatroban is a new thrombin inhibitor. Its mechanism of action is to bind and inactivate thrombin (factor Ⅱ a) directly.Compared with traditional anticoagulants, argatroban not only has the advantages of good anticoagulant effect and rapid onset, but also has high safety. Therefore, this study aims to verify the clinical efficacy of Argatroban in the treatment of PIS in a large population. In this study, 628 patients are expected to be enrolled into the study group. The experimental group and the control group are selected by dynamic random method. Both groups are given standard medical treatment, including routine antiplatelet, blood pressure control, statins to stabilize plaque, etc. The control group is only given standard medical treatment. In the experimental group, Argatroban is used on the basis of standard medical treatment. Both groups are treated for 7 days, and the second-class prevention standard medical treatment is given from the 8th to the 90th day. The main outcome measure is the good prognosis rate at the third month after PIS. The good prognosis was defined as the modified Rankin Scale (mRS) ≤ 3.

Conditions

  • Acute Progressive Ischemic Stroke

Interventions

  • ArgatrobanDrug

    Argatroban plus standard medical treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. proportion of patients with a 3-month modified Rankin Scale (mRS) score≤ 3Time frame: 3 months

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • People's Hospital of Anji

    Anji, China

  • Jiaxing Second Hospital

    Jiaxing, China

  • Ninghai First Hospital

    Ninghai, China

  • Quzhou Kecheng People's Hospital

    Quzhou, China

  • Tongxiang Diyi Renmin Hospital

    Tongxiang, China

  • Min Lou

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.